Immune-mediated coagulopathy: A case report

Pharmacotherapy

Volumn 29, Issue 7 PART 2, 2009, Pages

  Naoum, Joseph J ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Hemostasis; IMC; Immune mediated coagulopathy; Postoperative bleeding; Thrombin; Topical hemostat

Indexed keywords

BLOOD CLOTTING FACTOR 5; FRESH FROZEN PLASMA; LIVER ENZYME; THROMBIN; THROMBIN INHIBITOR; THROMBIN JMI; UNCLASSIFIED DRUG; VITAMIN K GROUP;

ABDOMINAL PAIN; ABDOMINAL SURGERY; ADULT; ANAMNESIS; ANTICOAGULANT THERAPY; ARTERY DISEASE; ARTICLE; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; ERYTHROCYTE CONCENTRATE; FLANK PAIN; HEMOSTASIS; HUMAN; IMMUNE MEDIATED COAGULOPATHY; INTERNATIONAL NORMALIZED RATIO; LAPAROTOMY; MALE; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE PERIOD; PREOPERATIVE CARE; PROTHROMBIN TIME; RETROPERITONEAL HEMATOMA; REVASCULARIZATION; THROMBIN TIME; ULCER;

ANIMALS; ANTIFIBRINOLYTIC AGENTS; BLOOD COAGULATION DISORDERS; BLOOD COMPONENT TRANSFUSION; CATTLE; HEMOSTASIS, SURGICAL; HEMOSTATICS; HUMANS; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; THROMBIN; VITAMIN K;

EID: 68049131444     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.pt2.13S     Document Type: Article

References (15)

1. Vine AK. Recent advances in haemostasis and thrombosis. Retina 2009;29:1-7.
2. Diesen DL, Lawson JH. Bovine thrombin: history, use, and risk in the surgical patient. Vascular 2008;16(suppl 1):S29-36.
3. Zehnder JL, Leung LL. Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin. Blood 1990;76:2011-2016
4. Ortel TL, Charles LA, Keller FG, et al. Topical thrombin and acquired coagulation factor inhibitors: clinical spectrum and laboratory diagnosis. Am J Hematol 1994;45:128-135
5. Chouhan VD, De La Cadena RA, Nagaswami C, Weisel JW, Kajani M, Rao AK. Simultaneous occurrence of human antibodies directed against fibrinogen, thrombin, and factor V following exposure to bovine thrombin: effects on blood coagulation, protein C activation and platelet function. Thromb Haemost 1997;77:343-349 (Pubitemid 27084928)
6. Dorion RP, Hamati HF, Landis B, Frey C, Heydt D, Carey D. Risk and clinical significance of developing antibodies induced by topical thrombin preparations. Arch Pathol Lab Med 1998;122:887-894 (Pubitemid 28485270)
7. Sarfati MR, DiLorenzo DJ, Kraiss LW, Galt SW. Severe coagulopathy following intraoperative use of topical thrombin. Ann Vasc Surg 2004;18:349-351
8. Kapoor A, Cortese Hassett A, Bontempo F. Lack of response bleeding from acquired factor V inhibitor to recombinant human factor VIIa concentrate [abstract]. Blood 2005; 106(11):4099.
9. Kirkeby KM, Aronowitz P. Acquired factor V inhibitor: a common and avoidable complication of topical bovine thrombin application [letter]. Am J Med 2005;118:805. (Pubitemid 40897676)
10. Lawson JH, Lynn KA, Vanmatre RM, et al. Antihuman factor V antibodies after use of relatively pure bovine thrombin. Ann Thorac Surg 2005;79:1037-1038
11. Shah AK, Moreno-Aspitia A. Acquired factor V inhibitor and single exposure to autologous growth factor. Thromb Res 2005;116:87-89 (Pubitemid 40546329)
12. Crow SS, Sullivan VV, Aysola AE, et al. Postoperative coagulopathy in a pediatric patient after exposure to bovine topical thrombin. Ann Thorac Surg 2007;83:1547-1549 (Pubitemid 46440760)
13. Savage WJ, Kickler TS, Takemoto CM. Acquired coagulation factor inhibitors in children after topical bovine thrombin exposure. Pediatr Blood Cancer 2007;49:1025-1029
14. Johnson & Johnson Wound Management. Evithrom (topical human thrombin) package insert. Somerville, NJ; 2007.
15. ZymoGenetics, Inc. Recothrom (thrombin, topical, recombinant) package insert. Seattle, WA; 2008.